Barclays analyst Emily Field lowered the firm’s price target on Sanofi (SNY) to EUR 115 from EUR 125 and keeps an Overweight rating on the shares.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability progression (CDP) in people with non-relapsing secondary progressive ...

Claims database analysis allows for estimation of real-world treatment patterns, including persistence with individual therapies, and the strength of our analysis derives from the large ...

Methods Data from Clinformatics™ for DataMart affiliated with OptumInsight was used to identify patients using DMT between 2001 and 2010. Patients with 12, 24, and 36 months of follow-up were ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s ...

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding ...